Pan-cancer; monotherapy and combination immunotherapy, including anti-PD-L1 combinations
Key Differentiation:
High-affinity SIGLEC-15 blockade with a distinct epitope, human/cynomolgus cross-reactivity, favorable preclinical efficacy and safety, and flexibility for monotherapy or combination immunotherapy
Partnership Opportunity:
Available for ex-China licensing and co-development
